The stars lined up for the trailblazing gene-editing companies in fall 2020 - first came the Nobel Prize for the CRISPR developers, followed by encouraging clinical data that were presented at the American Society of Hematology’s Annual Meeting.
In the report, we looked at what gene editing is and went through the major platforms. We have identified a few applications that have yielded preliminary results and looked at the progress of the key players in each field. For the listed companies focusing on therapeutics, they have announced the benefits seen in patients with hemoglobinopathies who were treated with their experimental CRISPR treatments.
Separately, we have looked at some emerging applications that are developed by private start-up companies aiming to alleviate the organ shortage problem and more sustainable agriculture. We believe the 2023 global market value for CRISPR technology of $218.9bn, as projected by BCC Research, has not taken into consideration the potential and speed of development in these fields.